Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Global hematological cancer market set to grow rapidly across all treatment segments in the next five years, says GlobalData

The hematological cancer therapy market is diverse and highly genericized, with chemotherapies currently accounting for the highest number of marketed drugs. However, the availability of more targeted and innovative therapies means that sales of antibodies, cell therapies and targeted therapies are all set to increase to 2027 at Compound Annual Growth Rates (CAGRs) of 11.5%, […]
Read more

Approval of first interchangeable biosimilar insulin will increase competition with payer contracts, says GlobalData

When it comes to insulin choice, price is currently the biggest barrier, as insulin brand preference is primarily determined not by a doctor, but through payer contracts with pharma companies, according to GlobalData. The leading data and analytics company notes that while patients will be increasingly prescribed Viatris/Biocon’s Semglee (biosimilar insulin glargine-yfgn) over Sanofi’s Lantus […]
Read more

Gene therapies could revolutionize cardiovascular disease management offering a one-time treatment for conditions such as heart failure, says GlobalData

Gene therapies could revolutionize the management of chronic cardiovascular diseases (CVDs) such as heart failure, according to GlobalData. The leading data and analytics company notes that there are currently *87 CVD gene therapies currently in development, and they hold potential to vastly improve patients’ quality of life. Fiona Chisholm, Pharma Analyst at GlobalData comments: “As […]
Read more

Domestic pharma firms lead CAR-T therapy trials in China, says GlobalData

China’s overall focus within oncology research is increasing at a rapid pace. Moreover, the country recently approved its first chimeric antigen receptor (CAR)-T cell therapy. Against this backdrop, Chinese domestic pharma companies are found at the forefront of company-sponsored CAR-T cell therapy trials and are likely to dominate the CAR-T landscape, says GlobalData, a leading […]
Read more

Takeda’s TAK-994 shows potential for orexin agonists as narcolepsy treatment

Takeda Pharmaceutical’s TAK-994 has recently received breakthrough therapy designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1). The potential approval of TAK-994 could lead to the first treatment that increases orexin activity in patients with narcolepsy, says GlobalData, a […]
Read more

Novel diagnostic face masks that detect SARS-CoV-2 could offer enhanced method to detect and respond to Delta variant, says GlobalData

Following today’s news (18 August) that diagnostic face masks developed by the Massachusetts Institute of Technology (MIT) and Harvard University are about to be commercialized: Sultan Ahmed, Infectious Disease Analyst at GlobalData, a leading data and analytics company, offers his view: “GlobalData believes that the new diagnostic masks have the potential to create a large […]
Read more

Takeda leads the way among Big Pharma players in microbiome-targeting treatments, says GlobalData

Takeda is currently developing multiple microbiome-targeting agents through a number of collaborations with innovative small companies. Its latest partnership with Finch Therapeutics to advance FIN-524, a microbiome-targeting drug candidate for the treatment of ulcerative colitis (UC), into clinical development under the new name TAK-524, demonstrates Takeda’s commitment to pursuing novel microbiome-targeting therapeutic approaches in the […]
Read more

COVID-19 booster doses will help protect against variants, but will drive global vaccination inequality, says GlobalData

Following the news that the US government is planning to recommend COVID-19 booster doses for all residents eight months after full vaccination; Philipp Rosenbaum, PhD, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view: “Initial data from Pfizer/BioNTech, Moderna, AstraZeneca, and Novavax shows that a third dose of a COVID-19 […]
Read more

Bimekizumab new results in psoriasis pave way for potential best in class, says GlobalData

UCB, a global biopharmaceutical company, has recently presented new interim data from BE BRIGHT, an open-label extension (OLE) trial of an interleukin (IL)-17A/F inhibitor ‘bimekizumab’ for plaque psoriasis (PsO), at the 2021 American Academy of Dermatology (AAD) Summer Meeting. While the data are still preliminary, they strongly support a potential approval for bimekizumab in PsO […]
Read more

Australia set to reinforce cancer research with committed funding and research collaborations, says GlobalData

Cancer remains the leading cause of death in Australia. Against this backdrop, the government is supporting the home-grown oncology research with committed funding. Moreover, the research collaborations between the Australian institutes and pharma companies will further help expedite the overall research developments, says GlobalData, a leading data and analytics company. In June 2021, Australia announced […]
Read more

NK cell therapies promising and potentially available off-the-shelf for hematological and solid tumor treatment, says GlobalData

Natural killer (NK) cell therapies have the potential to be an effective, off-the-shelf treatment for a wide range of cancers. Analysis of NK cell therapies, currently in development, reveals that 57% of these are allogeneic therapies, and although development in hematological indications is more advanced, there are a high number of therapies being investigated in […]
Read more

Seres’ setback could make it harder for companies to get funding for microbiome-targeting therapies, says GlobalData

Seres Therapeutics’ announcement last month that it was discontinuing its ECO-RESET Phase IIb clinical trial (NCT03759041) investigating SER-287 in patients with mild-to-moderate ulcerative colitis (UC) is likely to increase the scrutiny on other therapies targeting the microbiome and make funding more challenging, says GlobalData, a leading data and analytics company. Chris Pilis, Immunology Analyst at […]
Read more

Axsome Therapeutics AXS-05 shows promising results in resistant depression treatment, says GlobalData

Axsome Therapeutics recently announced that its pipeline product AXS-05 (bupropion + dextromethorphan) achieved primary and key secondary endpoints in the MERIT Phase II Trial for the treatment of resistant depression (TRD). A large number of major depressive disorder (MDD) patients do not respond to the available treatments and are referred to as treatment-resistant. There is […]
Read more

Strong pipeline, favorable regulatory landscape to drive China biosimilar market, says GlobalData

China has seen a significant surge in biosimilar approvals over the last three years, with 13 new biosimilars approved during 2018–2021. Strong biosimilar pipeline and the latest regulation changes by the National Medical Products Administration (NMPA) are likely to drive China’s biosimilar market to new heights, says GlobalData, a leading data and analytics company. Prior […]
Read more
1 … 59 60 61 62 63 … 110